Frontlight ResearchEarly access
TerminatedNo phase
Investigating the Relationship Between Triglycerides and Fetal Overgrowth in Gestational Diabetes
Key facts
- Who runs it
- University of Kansas Medical Center
- Where
- Kansas City, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 7 people enrolled
- Started
- 10 Aug 2023
- Ended
- 1 Sept 2024
- Type of study
- Observational
- Treatments tested
- Observation
- Record updated
- 20 September 2024
- Why it stopped
- Unable to recruit subjects
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- singleton pregnancy
- diagnosis of GDM between 24-32 weeks
- BMI >= 30
Who cannot take part
- autoimmune conditions treated with medication
- illicit drug use
- Conditions known to impact fetal growth.These conditions can develop after study enrollment but cannot be present at enrollment
- chronic hypertension requiring medication
- fetal genetic conditions
- preeclampsia
- fetal growth restriction diagnosis
- smoking
- major fetal anomalies
Where in United States
- University of Kansas Medical CenterKansas City, United States
About the trial
What the trial wants to find out
This is a prospective, observational study which examines the association between maternal triglycerides in the antepartum period and fetal overgrowth in pregnancies complicated by gestational diabetes. Mothers are asked to provide 2 blood samples, undergo fingerstick blood measurements, and to have their newborns measured for body fat composition in the first 6 months of life.
The group in the trial
- Pregnancies with GDM and BMI > 30
Pregnancies with GDM diagnosed between 24-32 weeks and BMI \> 30.
Treatment: Observation
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 20 September 2024